The NRIF3/DIF-1/FASTKD2 pathway acts as a “death switch” in breast and prostate cancer cells, how FASTKD2 initiates the apoptotic response will allow for the development of therapeutic agents for the treatment of androgen-independent prostate cancer (28). This evidence concerns the gene FASTKD2 and prostate cancer.